1. Home
  2. QLGN vs PMAX Comparison

QLGN vs PMAX Comparison

Compare QLGN & PMAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • QLGN
  • PMAX
  • Stock Information
  • Founded
  • QLGN 1996
  • PMAX 2019
  • Country
  • QLGN United States
  • PMAX Hong Kong
  • Employees
  • QLGN N/A
  • PMAX N/A
  • Industry
  • QLGN Biotechnology: Pharmaceutical Preparations
  • PMAX
  • Sector
  • QLGN Health Care
  • PMAX
  • Exchange
  • QLGN Nasdaq
  • PMAX Nasdaq
  • Market Cap
  • QLGN 7.4M
  • PMAX 6.1M
  • IPO Year
  • QLGN N/A
  • PMAX 2024
  • Fundamental
  • Price
  • QLGN $2.85
  • PMAX $2.48
  • Analyst Decision
  • QLGN
  • PMAX
  • Analyst Count
  • QLGN 0
  • PMAX 0
  • Target Price
  • QLGN N/A
  • PMAX N/A
  • AVG Volume (30 Days)
  • QLGN 3.4M
  • PMAX 1.5M
  • Earning Date
  • QLGN 11-14-2025
  • PMAX 09-23-2025
  • Dividend Yield
  • QLGN N/A
  • PMAX N/A
  • EPS Growth
  • QLGN N/A
  • PMAX N/A
  • EPS
  • QLGN N/A
  • PMAX N/A
  • Revenue
  • QLGN N/A
  • PMAX $4,799,100.00
  • Revenue This Year
  • QLGN N/A
  • PMAX N/A
  • Revenue Next Year
  • QLGN N/A
  • PMAX N/A
  • P/E Ratio
  • QLGN N/A
  • PMAX N/A
  • Revenue Growth
  • QLGN N/A
  • PMAX N/A
  • 52 Week Low
  • QLGN $1.61
  • PMAX $1.87
  • 52 Week High
  • QLGN $8.81
  • PMAX $27.92
  • Technical
  • Relative Strength Index (RSI)
  • QLGN 39.72
  • PMAX 56.28
  • Support Level
  • QLGN $2.66
  • PMAX $2.52
  • Resistance Level
  • QLGN $3.36
  • PMAX $2.90
  • Average True Range (ATR)
  • QLGN 0.55
  • PMAX 0.30
  • MACD
  • QLGN -0.17
  • PMAX -0.11
  • Stochastic Oscillator
  • QLGN 5.74
  • PMAX 7.23

About QLGN Qualigen Therapeutics Inc.

Qualigen Therapeutics Inc is an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's program, QN-302, is an investigational small-molecule G-quadruplexes (G4)-selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells.

About PMAX Powell Max Limited Class A Ordinary Shares

Powell Max Ltd is an financial communications services provider. Its financial communications services cover a full range of financial printing, corporate reporting, communications and language support services from inception to completion, including typesetting, proofreading, translation, design, printing, electronic reporting, newspaper placement and distribution. It operates in a single business segment which is the provision of corporate financial communications and financial printing services. All operations are carried in Hong Kong.

Share on Social Networks: